Year All2026202520242023202220212020 News Releases Fractyl Health Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates Mar 24, 2026 Read More Fractyl Health to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Updates on March 24, 2026 Mar 17, 2026 Read More Fractyl Health Completes Randomization in REMAIN-1 Pivotal Cohort of Revita® for Post-GLP-1 Weight Maintenance Feb 26, 2026 Read More Fractyl Health Announces Compelling 6-Month Randomized REMAIN-1 Midpoint Data Showing Durable Weight Maintenance with Revita® After GLP-1 Discontinuation Jan 29, 2026 Read More Fractyl Health Appoints Lara Smith Weber as Chief Financial Officer to Support Commercial-Stage Preparedness Jan 06, 2026 Read More Fractyl Health Enters a Catalyst-Rich 2026 Positioned to Define the Post-GLP-1 Weight Maintenance Therapeutic Category Jan 05, 2026 Read More Investor Relations Contacts Brian Luque, Head of Investor Relations and Corporate DevelopmentEmail: ir@fractyl.com Phone: 951.206.1200 Email Alerts Investor FAQs Compliance Hotline
Year All2026202520242023202220212020 News Releases Fractyl Health Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates Mar 24, 2026 Read More Fractyl Health to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Updates on March 24, 2026 Mar 17, 2026 Read More Fractyl Health Completes Randomization in REMAIN-1 Pivotal Cohort of Revita® for Post-GLP-1 Weight Maintenance Feb 26, 2026 Read More Fractyl Health Announces Compelling 6-Month Randomized REMAIN-1 Midpoint Data Showing Durable Weight Maintenance with Revita® After GLP-1 Discontinuation Jan 29, 2026 Read More Fractyl Health Appoints Lara Smith Weber as Chief Financial Officer to Support Commercial-Stage Preparedness Jan 06, 2026 Read More Fractyl Health Enters a Catalyst-Rich 2026 Positioned to Define the Post-GLP-1 Weight Maintenance Therapeutic Category Jan 05, 2026 Read More